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Objective: Quantification of gait with wearable technology is promising; recent cross-sectional studies showed that
gait characteristics are potential prodromal markers for Parkinson disease (PD). The aim of this longitudinal prospective
observational study was to establish gait impairments and trajectories in the prodromal phase of PD, identifying which
gait characteristics are potentially early diagnostic markers of PD.
Methods: The 696 healthy controls (mean age = 63  7 years) recruited in the Tubingen Evaluation of Risk Factors for
Early Detection of Neurodegeneration study were included. Assessments were performed longitudinally 4 times at
2-year intervals, and people who converted to PD were identified. Participants were asked to walk at different speeds
under single and dual tasking, with a wearable device placed on the lower back; 14 validated clinically relevant gait
characteristics were quantified. Cox regression was used to examine whether gait at first visit could predict time to PD
conversion after controlling for age and sex. Random effects linear mixed models (RELMs) were used to establish longi-
tudinal trajectories of gait and model the latency between impaired gait and PD diagnosis.
Results: Sixteen participants were diagnosed with PD on average 4.5 years after first visit (converters; PDC). Higher
step time variability and asymmetry of all gait characteristics were associated with a shorter time to PD diagnosis.
RELMs indicated that gait (lower pace) deviates from that of non-PDC approximately 4 years prior to diagnosis.
Interpretation: Together with other prodromal markers, quantitative gait characteristics can play an important role in
identifying prodromal PD and progression within this phase.
ANN NEUROL 2019;86:357–367
Parkinson disease (PD) is a progressive neurodegenera-tive disorder including a prodromal period during
which the disease has started but the definitive motor and
nonmotor symptoms to permit a diagnosis have not yet
appeared.1–3 Identifying people at this stage is of significant
interest, as this is the time in which neuroprotective thera-
pies should be delivered, when they become available.
Previous research has tried to characterize the pro-
dromal interval of PD in terms of features and duration.
This prodromal PD phase has been estimated by previous
retro- and prospective studies to be between 3 and
15 years, with this period varying depending on type of
marker and patient-related factors such as age.4,5 Utiliza-
tion of clinical scales6 (ie, the Unified Parkinson Disease
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Rating Scale [UPDRS]) and neuropathological studies
(based on cell loss in the substantia nigra) suggest a pro-
dromal period of approximately 5 years.7
Idiopathic rapid eye movement sleep behavior disor-
der (RBD) is a particularly interesting prodromal marker.
More than 50% convert to PD or similar diseases (such as
dementia with Lewy bodies) with an average duration of
the overall prodromal phase of 13 years8 and a motor
phase of 4.5 years.9–11 A study using simple methods for
description of motor abnormalities (UPDRS and Timed
Up and Go test) suggests that first abnormalities in gait
precede diagnosis by up to 4.4 to 6.3 years.10 A quantita-
tive cross-sectional evaluation of normal-pace walking in
RDB participants found subtle changes of velocity,
cadence, and variability of gait compared to controls.12
Comparable results were found in a quantitative cross-
sectional evaluation of gait—here, however, only during
challenging (dual-task) conditions—in LRRK2 mutation
carriers who showed increased gait variability and
decreased amplitude of the dominant peak of the acceler-
ometer signal.13 Another cross-sectional study14 showed
increased arm-swing variability in LRRK2 mutation car-
riers that was basically visible in non-PD and PD state
under challenging conditions (ie, dual-task conditions).
These latter studies therefore cannot differentiate between
initial abnormalities in the central gait network of RBD
and LRRK2 cohorts (which can be entirely independent
of dynamic processes happening in a prodromal PD
phase) and “real” prodromal PD markers, thus highlight-
ing the need for prospective longitudinal and population-
based studies.
The use of wearable sensors to measure gait is show-
ing significant promise.15–20
The aim of this longitudinal prospective observation
study over 6 years in a cohort of healthy controls (HCs)
was therefore to investigate whether a comprehensive set
of gait characteristics measured with wearable technology,
that is, a wearable device, can define prodromal PD by
(1) evaluating if gait characteristics can predict risk of con-
version, (2) estimating the year-on-year change in gait
characteristics, and (3) identifying the time at which
changes in gait would start being evident prior to diagno-
sis. We hypothesized that (1) selected gait characteristics
predict future PD conversion, (2) gait declines continu-
ously during the prodromal phase, and (3) first gait
changes in future PD converters (PDCs) appear 4 to
5 years prior to diagnosis.
Subjects and Methods
Participants
Data were collected longitudinally at 2-year intervals between
2009 and 2016 (T1–T4). Six hundred and ninety-six HCs
recruited in the Tubingen Evaluation of Risk Factors for Early
Detection of Neurodegeneration (TREND) study were
assessed.21,22 Participants were included in the study if they were
aged 50 to 80 years and were excluded if they had any orthope-
dic or cardiothoracic conditions that might have markedly
affected their walking or safety during the testing sessions. To
maximize generalizability of the results, we included the whole
TREND cohort.
Ethics, Consent, and Permissions
The ongoing TREND study is being performed by the Depart-
ments of Neurology and Psychiatry of the University Hospital
Tübingen. It is being conducted according to the declaration of
Helsinki and has ethical approval from the ethics committee of
the Medical Faculty, University of Tübingen (90/2009BO2). All
participants signed an informed consent form prior to testing.
Demographic and Clinical Measures
Age, sex, body mass index (BMI), years of education (defined by
the International Standard Classification of Education23) Beck
Depression Inventory I score,24 and self-reported depression25
were recorded for each participant. The Movement Disorders
Unified Parkinson’s Disease Rating Scale part III (MDS-
UPDRS-III), Mini-Mental State Examination, and Consortium
to Establish a Registry for Alzheimer’s Disease (CERAD)26 were
among various tests in the assessment battery.22 Tremor was also
defined retrospectively based on MDS-UPDRS-III following
Bain,27 considering what the movement specialists evaluated as
more than physiological and mild tremors during a TREND visit
and persisting in the following TREND visit(s). Inclusion criteria
of the TREND study were being a healthy adult older than
50 years and being free of significant hearing or visual impair-
ments. Exclusion criteria were a diagnosis of a neurodegenerative
disease, stroke, or inflammatory central nervous disease or the
administration of dopaminergic or antipsychotic drugs.
The prodromal PD probability score was calculated for all
study visits according to Berg et al.1 The following parameters
were used: age for the pretest probability and for the posttest
probability, risk markers (sex, smoking status, family history for
PD, and substantia nigra hyperechogenicity status),28 and pro-
dromal markers (subthreshold parkinsonism defined as a MDS-
UPDRS-III total score above 6 points excluding postural and
action tremor), RBD assessed by the RBD screening
questionnaire,29 hyposmia assessed by the Sniffin’ Sticks test bat-
tery30 using normative values,31 depression (self-reported history
of major depression or acute major depression25), symptomatic
orthostatic hypotension, urinary dysfunction, erectile dysfunc-
tion, and constipation assessed by the Unified Multiple System
Atrophy Rating Scale.32
Laboratory Data Collection: Equipment and Gait
Protocol
Each participant wore a device, either DynaPort (McRoberts, the
Hague, the Netherlands; 100 Hz; T1, T2) or Opal (APDM,
Portland, OR; 128Hz; T3, T4), located on the area of the fourth
and fifth lumbar vertebrae (L4, L5; Fig 1A). Participants were
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asked to perform intermittent straight line walking trials over a
20m walkway under 4 different conditions: (1) single task at
their usual (preferred) speed, (2) single task at fast speed, (3) dual
task at fast speed with checking boxes (participants marked as
many boxes as possible on a sheet of paper on a clipboard as fast
as possible with a cross using a pen, defined as dual task 1), and
FIGURE 1: Clinic assessment of gait characteristics: (A) Example of body worn monitor placement and setup for walking data
collection. (B) Raw vertical acceleration processing: data extraction and segmentation (signal segments in dotted black lines)
from walking conditions (in order: single task at fast speed, single task at usual speed, dual task 1, and dual task 2). (C) Example
of gait characteristic evaluation from a walking bout. (D) Data output: conceptual model of gait representing 5 domains and
14 gait characteristics.
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(4) dual task at fast speed with serial subtractions (counting
backward in sevens, defined as dual task 2; Fig 1B).21
Fourteen gait characteristics comprising 5 domains (pace,
variability, rhythm, asymmetry, and postural control; Fig 1C, D),
representative of a conceptual model of gait,33 were evaluated from
the accelerometer signals with a validated gait analysis algorithm
from our group, which are extensively described.34,35 Briefly, triax-
ial acceleration signals were downloaded to a computer, segmented
into individual walking trials using time stamps, and analyzed by a
bespoke MATLAB (R2015a) program (see Fig 1B). All 128Hz
data (APDM) were down-sampled to 100Hz (frequency of
the Dynaport). Accelerometer signals were transformed to a
horizontal–vertical coordinate system36 and filtered with a fourth-
order low pass Butterworth filter at 20Hz.37–39 The initial contact
(IC; heel strike) and final contact (FC; toe off) events within the
gait cycle were identified from the Gaussian continuous wavelet
transform of the vertical acceleration. IC and FC detection allowed
the estimation of step, stance, and swing time.34 The IC events
were also used to estimate step length using the inverted pendu-
lum model.39 To estimate a value for step velocity, we utilized the
simple ratio between step distance (length) and step time.34 To
calculate variability characteristics (eg, step time variability), the
standard deviation (SD) from all steps (left and right combined)
was calculated. Asymmetry characteristics (eg, step time asymme-
try) were determined as the average absolute difference between
left and right steps (alternating) for each walking pass.34
Statistical Analysis
Statistical analysis was carried out using SPSS v24. Normality of
data and homoscedasticity were tested with Shapiro–Wilk test
and Levene’s test of equality of variances, respectively. Descrip-
tive statistics were reported as means and SDs.
The analysis had 3 key parts, according to our initially
mentioned aims and hypotheses.
Defining the Predictive Value of First Visit Gait
Characteristics to Identify Risk of PD Conversion. For this
purpose, Cox regression was performed, controlling for age
at first visit and sex (male, female) entered as an initial
block, before entering the gait characteristics in block
2. BMI and years of education at first visit were considered
as covariates; however, they did not contribute significantly
and so were not included in the final model. After consider-
ing each gait characteristic individually, we computed both
backward and forward conditional models to examine
whether a combination of gait characteristics could better
predict conversion to PD. Age at first visit and sex were
again entered in the first block, and then all gait variables
were entered in the second block. Given the exploratory
nature of this analysis, we used a threshold of p < 0.05 to
guide statistical interpretation and did not make adjust-
ments for multiple comparisons.12,40,41 However, we pro-
vide the p value for each comparison so that the reader may
assess the statistical strength of our findings.
Estimate the Yearly Change for Each Gait
Characteristic. For this purpose, random effects linear
mixed models were used. The intercept and yearly slope
were modelled as random effects, using a diagonal covari-
ance structure. Sex was modelled as a fixed effect. For
non-PDC, age was centered about the mean PDC group
age at first visit. For PDC, age was centered about their
individual date of diagnosis. T tests (Welch variant to
accommodate unequal variance) were used to test for dif-
ferences in gait at the time of PD diagnosis and yearly
change in gait. Data collected after PD diagnosis was
excluded for longitudinal analysis to avoid the potential
confounding effects of medication and clinical manage-
ment on gait.
Estimate How Many Years prior to Diagnosis Gait of PDC
Differed from Non-PDC. For this purpose, we used a
recently published method10 that divided the difference in
gait between non-PDC and PDC at the time of diagnosis
by the yearly change of the PDC. To reduce the number
of models, we focused on gait characteristics which chan-
ged over time in the PDC group in conjunction with a
group difference at the time of PD diagnosis. To
TABLE 1. Clinical and Demographic Characteristics
for the Whole TREND Cohort, N = 696
Characteristic Value
Female, n (%) 378 (54)
Age, yr, mean (SD) 63 (7)
BMI, kg/m2, mean (SD) 26 (4)
Education, yr, mean (SD) 15 (3)
MMSE, 0–30, mean (SD) 29 (1)
CERAD, 0–100, mean (SD) 85 (7)
Probability score mean (SD) 7 (14)
Tremor, n (%) 35 (5)
BDI-I score mean (SD) 8 (7)
Self-reported depression, n (%) 265 (38)
Probability score indicates individual probability of prodromal
Parkinson disease (PD) score, with inclusion of the following features:
substantia nigra hyperechogenicity, probable rapid eye movement
sleep behavior disorder, subthreshold parkinsonism, hyposmia, erec-
tile dysfunction, constipation, and PD family history.28
BDI-I = Beck Depression Inventory I; BMI = body mass index;
CERAD = Consortium to Establish a Registry for Alzheimer’s Disease
neuropsychological battery26; MMSE = Mini-Mental State Examina-
tion50; SD = standard deviation; TREND = Tubingen Evaluation of
Risk Factors for Early Detection of Neurodegeneration.
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accommodate for unequal proportion of females between
the groups, estimated means were calculated assuming
50% of males and females in both groups.
Results
Clinical, demographic, and cognitive descriptors of the
whole TREND study cohort are shown in Table 1. Reten-
tion rates with respect to first visit (T1) were 90.9% at
T2, 83% at T3, and 76.5% at T4. A higher probability of
prodromal PD score in the control cohort at first visit was
associated with dropping out of the study sooner; how-
ever, this association became nonsignificant after control-
ling for age at first visit and sex (p = 0.129). Among the
696 participants, 16 were diagnosed with PD on average
4.5 years after the first visit (future PDCs) and
680 remained non-PDC. For descriptive purposes only,
we report details of the PDC and non-PDC groups in the
Supplementary Table.
Predicting PD Conversion with Gait
Characteristics
Descriptive data for each gait characteristic under normal
walking conditions for the whole cohort are shown in
Table 2.
Cox regression revealed that, during single task at
usual-speed walking, greater gait variability (step and
swing time) and asymmetry (step, swing, and stance time
and step length) significantly predicted PD conversion.
Forward stepwise Cox regression showed the combination
of older age, male sex, and more asymmetric swing time
and step length best predicted conversion to PD (see
Table 2). Backward stepwise Cox regression resulted in a
larger combination of predictors (older age, male sex,
quicker step time, greater variability of step time and step
length, and more asymmetric step length; Fig 2). We
repeated the analysis for the remaining walking tasks: for
single task at fast speed and dual task 2 walking condi-
tions, only a higher step length asymmetry significantly
predicted a shorter time to PD conversion (p ≤ 0.018); for
dual task 1 walking condition, none of the variables signif-
icantly predicted PD conversion. We also checked for cor-
relation between the gait variability and asymmetry and
substantia nigra hyperechogenicity, which showed R2
values below 0.12 (data not shown). In light of these
results, we focused on single task at usual-speed walking
for subsequent analyses. Results of the other walking con-
ditions are not reported but are available upon request.
Change in Gait Characteristics over Time
In PDC, over time, step velocity and step length reduced,
but step time, stance time, and stance time asymmetry
increased (Table 3).
Determining Onset of Change in Gait
Characteristics prior to PD Conversion
Step velocity and step length were the only variables that dem-
onstrated significant change over time in the group of people
who subsequently converted to PD using the non-PDC as a
reference, in conjunction with a group difference at the time
of PD diagnosis (all pace and variability characteristics). There-
fore, step velocity and step length were chosen to estimate
how early the gait of PDC deviated from “normal” (ie, non-
PDC). Step velocity deviated from non-PDC 3.3 years
(95% confidence interval [CI] = 2.0–9.3) and step length
deviated from non-PDC 4.1 years (95% CI = 2.7–9.15)
prior to diagnosis of PD (Fig 3). We recalculated these esti-
mates controlling the decline of step velocity and length over
time in the non-PDC, resulting in 1.7 years latency for gait
velocity and 3.1 years for step length.
Discussion
This is the first study to our knowledge to comprehensively
examine gait in a cohort of older adults at risk of converting
to PD and to carry out longitudinal follow-up to conver-
sion. We were able to show that gait discriminates future
PD converters from HCs up to approximately 4 years prior
to clinical diagnosis. Moreover, we show that gait character-
istics have the potential to predict conversion to PD and
can relevantly add to a panel of prodromal markers for the
definition of persons at substantially increased risk for
PD. To ensure robustness of the findings also with respect
to cognition, we compared results of an extensive neuropsy-
chological test (CERAD) between 2 investigated cohorts,
with results that were not significantly different, and we
controlled for years of education in our analysis. Our study
presents data obtained from wearable technology (1 sensor
at the lower back) and validated gait analysis algorithms,
which renders this approach a feasible and useful paradigm
even for screening in large cohorts and general practice.
Can Gait Predict PD Conversion?
A novel aspect of this study is the longitudinal assessment
of gait impairments, associated with PD prior to the onset
of clinically significant motor deficits and diagnosis, with
a wearable device during a series of walking tasks. This
method presented a unique opportunity to observe
whether gait could predict risk of PD conversion.
We hypothesized that selected gait characteristics
would predict PD conversion.
Indeed, Cox regression indicated that greater gait
variability (step and swing time) and asymmetry (step,
swing, and stance time and step length) significantly
predicted a shorter time to PD conversion during the sin-
gle task at usual-speed walking conditions. Only step
length asymmetry (fast speed and dual task 1 tasks)
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significantly predicted a shorter time to PD conversion in
the more challenging walking conditions, including dual
tasking. This observation is interesting in the light of pre-
vious studies focusing on gait alterations in cohorts with
potentially increased risk for PD.13
To the best of our knowledge, only cross-sectional
studies are currently published reporting about the poten-
tial of quantitative gait characteristics; some found differ-
ences between persons with increased risk of developing
PD and controls under self-selected gait speed,12,14 and
some found differences between populations at risk and
controls only under more challenging conditions (eg, dual
task).13,14 This difference with respect to our findings may
be due to a different population being investigated (eg,
nonmanifesting LRRK2-G2019S mutation carrier vs PDC)
and a distinct dual task protocol (we investigated dual task
at fast speed rather than preferred speed like previous stud-
ies) and also gait focus (upper limbs vs lower limbs).
Whatever the reasons are for the previously men-
tioned observations, we provide here the first strong







Forward Stepwise Model Backward Stepwise Model
β (CI 95%) β (CI 95%) p β (CI 95%) p
Sex, F −1.7 (−3.3 to −0.2) 0.025a −2.0 (−3.5 to −0.4) 0.013a −2.4 (−4.2 to −0.7) 0.007a
Age 0.088 (−0.003 to 0.179) 0.058 0.083 (−0.013 to 0.180) 0.091 0.100 (−0.004 to 0.204) 0.058
Pace
Step velocity, m/s 1.173 (0.162) −1.1 (−4.7 to 2.5) 0.561
Step length, m 0.588 (0.066) −5.5 (−15.2 to 4.3) 0.274
Swing time Var, s 0.021 (0.014) 27.6 (2.2 to 52.9) 0.033a
Variability
Step velocity Var, m/s 0.088 (0.040) 4.2 (−8.4 to 16.9) 0.511 −16.6 (−36.6 to 3.4) 0.103
Step length Var, m 0.035 (0.016) 21.4 (−10 to 52.9) 0.181
Step time Var, s 0.026 (0.017) 24.4 (2.7 to 46) 0.028a 50.9 (12.5 to 89.3) 0.009a
Stance time Var, s 0.024 (0.014) 24.5 (−2.8 to 51.9) 0.079
Rhythm
Step time, s 0.507 (0.043) 0.3 (−8.5 to 9.2) 0.938 −17.1 (−34.9 to 0.7) 0.060
Swing time, s 0.353 (0.037) 1.8 (−13.9 to 17.4) 0.826
Stance time, s 0.660 (0.057) −3.7 (−14.3 to 7) 0.499
Asymmetry
Step time Asy, s 0.032 (0.032) 16.5 (5.6 to 27.5) 0.003a
Swing time Asy, s 0.025 (0.025) 20.2 (7.2 to 33.2) 0.002a 17.3 (2.9 to 31.8) 0.019a
Stance time Asy, s 0.025 (0.025) 19.7 (6.4 to 33.0) 0.004a
Postural control
Step length Asy, m 0.025 (0.021) 29.8 (14.8 to 44.9) <0.001a 26.4 (10.9 to 41.9) 0.001a 29.6 (13.3 to 45.8) <0.001a
Cox regression predicting time (in months) to PD conversion for individual gait characteristics (base model) and for the combination of gait character-
istics (forward and backward stepwise regression). Age and sex were entered into the first block prior to entering gait characteristics in the second block.
Gait characteristics are presented for the whole Tubingen Evaluation of Risk Factors for Early Detection of Neurodegeneration cohort (n = 696) for a
single task at the usual-speed walking condition.
ap < 0.05.
Asy = asymmetry; CI = confidence interval; F = female; PD = Parkinson disease; Var = variability; β = unstandardized beta values where a larger beta
value refers to an increase in hazard and so a shorter time to diagnosis.
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evidence that self-selected pace may be a promising gait
paradigm for the investigation of the prodromal PD phase
and of the risk of PD conversion.
Interestingly we found that step length asymmetry
was the best single predictor in the regression model
during usual (preferred)-speed walking. This is in line
with the known impaired ability to regulate alternate
(left/right) steps in PD, and gait asymmetry has been
shown to be a sensitive measure of gait (in)stability.13–15
At the same time, the asymmetric nature of PD is
evidently important in detecting early risk. The higher
asymmetry (poorer performance) of PDC and the fact
that step time asymmetry strongly predicts risk of PD
would corroborate the theory that subtle changes in gait
asymmetry could reflect prodromal motor alterations,
reduced ability of compensatory strategies, and a possi-
ble early manifestation of alterations to the central gait
network in PDC.13
Our results support the asymmetric nature, even
before diagnosis, of PD, in agreement with previous work
FIGURE 2 Kaplan–Meier curves illustrating shorter time to Parkinson disease (PD) diagnosis using different combinations of first
visit gait variables derived from univariate analysis and forward and backward stepwise Cox regression. (A) Greater step length
asymmetry at first visit (adjusted for age and sex). (B) Combination of greater step length and swing time asymmetry (adjusted
for age and sex). (C) Combination of greater step length asymmetry, higher variability of step velocity and step time, and
quicker step time (adjusted for age and sex). Low and high risk were determined as higher than (high risk) and lower than (low
risk) the hazard models created from models described in Table 2.
TABLE 3. Yearly Change of Gait Characteristics of the PDCs
Single Task at Usual Speed PDC Intercept (SD)a PDC Yearly Change (SD)
Pace
Step velocity, m/s 1.007 (0.359) −0.0295 (0.0353)b
Step length, m 0.514 (0.158) −0.0134 (0.0138)b
Swing time Var, s 0.040 (0.032) 0.0021 (0.0004)
Variability
Step velocity Var, m/s 0.125 (0.057) 0.0021 (0.0101)
Step length Var, m 0.047 (0.036) 0.0023 (0.0045)
Step time Var, s 0.043 (0.037) 0.0008 (0.0056)
Stance time Var, s 0.042 (0.031) 0.0021 (0.0043)
Rhythm
Step time, s 0.514 (0.083) 0.0028 (0.0034)b
Swing time, s 0.371 (0.062) 0.0015 (0.0067)
Stance time, s 0.663 (0.119) 0.0044 (0.0067)b
Asymmetry
Step time Asy, s 0.040 (0.065) −0.0032 (0.0081)
Swing time Asy, s 0.041 (0.063) −0.0001 (0.0046)
Stance time Asy, s 0.044 (0.062) 0.0006 (0.0006)
Postural control
Step length Asy, m 0.038 (0.079) −0.0008 (0.0042)
Intercept and yearly change data for gait characteristics of the PDCs for a single task in the usual-speed walking condition. Values are presented as
mean (standard deviation) and estimated for an equal proportion of males and females in each group.
aAt diagnosis.
bWithin-group yearly change of gait p < 0.05.
Asy = asymmetry; PDC = Parkinson disease converter; SD = standard deviation; Var = variability.
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showing that increased gait asymmetry is typical in PD
gait.42–44
In agreement with our findings, previous work
involving people at increased risk for PD (RBD patients)
showed an association between PD risk and gait variabil-
ity.12 This is an interesting finding when thinking about
the typically more variable gait observed in PD patients
and the importance given to gait variability measures in
PD and disease progression,45–47 also when quantified
with wearable technology.48 Thus, these results add to the
debate of whether higher gait variability may be “good” or
“bad” depending on observed populations (eg, PD, HC,
fallers, etc); in this case, our study would corroborate the
“badness” of higher variability, potentially representing the
start (or the worsening) of an impaired control of gait.
In contrast with previous work, our study found that
step velocity was not a significant predictor of PD conver-
sion; this could be due to the different population
observed (RBD vs PDC), walking protocol (10m vs 20m
walk), and measurement tools used (instrumented mat vs
wearable device).12
Although we focused on gait only and did not look at
arm swing during gait, our results partly support the finding
that higher gait asymmetry and variability (especially during
single task at usual-speed walking condition, less heightened
during dual task conditions) appear to be prodromal
markers for PD.14 Together these findings show specific dif-
ferences in gait characteristics that inform a nuanced under-
standing of gait changes during the prodromal PD stage.
Does Gait Change over Time in PD Converters?
Our second hypothesis was that gait changes in PDC
would decline continuously during the prodromal phase.
We found that over time, walking speed and step
length were reduced in both groups, but variability
increased. This finding is in agreement with previous stud-
ies that looked at gait progression in PD and found that
pace (step length) decreased over both shorter (ie,
18 months) and longer (ie, 36 months)49 periods of time.
When Does Gait Start to Change before
Conversion to PD?
Finally, we hypothesized that, based on previous
literature,10 first gait changes in PDC appear 4 to 5 years
prior to diagnosis. Our study confirms and complements
the demonstrated evidence that, in at risk groups, there
are subtle changes in gait prior to the onset of significant
motor symptoms and these may start about 4 years prior
to PD diagnosis.11,12 Although we used a different proto-
col and tools compared to previous studies (UPDRS and
Timed Up and Go test),10 we found comparable results.
Clinical Implications: Cross-sectional versus
Progression Gait Characteristics in Prodromal PD
Our results show promising cross-sectional (higher vari-
ability and asymmetry) and progression (step velocity and
step length) gait characteristics for the detection of the
prodromal PD phase. The different nature of these charac-
teristics is in our view not surprising, as they represent
FIGURE 3: The graph illustrates step velocity and step length at usual speed prior to diagnosis of Parkinson disease (Parkinson
disease converters [PDC]; gray lines indicate individuals, solid black line indicates PDC group mean) compared to the mean
walking speed of non-PDC at first visit (indicated by the dotted line). The 2 lines intersect approximately 3.3 years prior to PD
diagnosis for gait velocity and 4.1 years for step length, indicating the latency between early changes of gait and diagnosis.
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different concepts. Cross-sectional gait characteristics serve
as trait markers, to highlight people “at risk” of PD con-
version, whereas progression markers (mainly) depend on
the intra-individual dynamic of the characteristic over
time. We speculate that combining these characteristics
has even more potential than single parameters to identify
people at risk for clinically overt PD.
Limitations
Although this is, to our best knowledge, the first prospec-
tive longitudinal study on gait characteristics in prodromal
PD, we acknowledge that use of different wearable devices
may have impacted the variability of the data, and the lim-
ited number of PDCs may affect generalizability of the
results. Only 1 model of gait characteristics was included
in this work; in the future, other reported models and fea-
tures should be considered to identify the best measure
(or combination of measures) for risk prediction and clini-
cal decision-making. In addition, subtle changes in the
prodromal stages of gait necessarily result in wide CIs
when estimating how long prior to diagnosis changes in
gait occur.
Even though current assumptions about clinically
overt and prodromal stages of PD suggest that any mani-
festations that are nonmotor are “prodromal,” it is possible
that the gait abnormalities ascertained here correspond to
overlooked motor aspects falling beyond the resolution of
clinicians; they may, in a future in which quantitative
sensor-based gait assessments may be widespread, be
reclassified as early motor PD.
Even if our findings are consistent with previous
work, the combination of greater numbers of converters
and more complex nonlinear statistical models (not feasi-
ble here given the relatively moderate number of con-
verters) may yield more robust estimates.
We found that gait variability and asymmetry char-
acteristics seem to be the best predictors for the definition
of persons in this vulnerable phase before conversion to
clinical PD. Interestingly, we obtained the best results
from self-selected walking speed conditions without dual
tasking. Step velocity and step length seem to be the best
and most stable gait characteristics defining progression
during the prodromal PD phase.
Our results suggest that quantitative sensor-based
gait assessment may be considered part of an assessment
battery for definition of prodromal PD or with subclinical
motor manifestations.
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